Parkman Healthcare Partners’s Pulmonx LUNG Stock Holding History

Parkman Healthcare Partners’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$975K	Buy	755,636 +27,855	+4%	+$46K	0.1%	84
2025 Q4	$1.61M	Buy	727,781 +227,119	+45%	+$427K	0.15%	86
2025 Q3	$811K	Sell	500,662 -104,367	-17%	-$218K	0.08%	87
2025 Q2	$1.57M	Sell	605,029 -6,846	-1%	-$27K	0.18%	82
2025 Q1	$4.12M	Buy	611,875 +404,022	+194%	+$2.86M	0.49%	58
2024 Q4	$1.41M	Buy	207,853 +1,409	+0.7%	+$9.28K	0.19%	81
2024 Q3	$1.71M	Buy	+206,444	New	+$1.49M	0.22%	80

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's LUNG Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Pulmonx (LUNG) stake by 3.8% in Q1 2026, buying an estimated $46K and bringing the position to 755,636 shares worth $975K. The position accounts for 0.1% of the portfolio, ranked #84.

Parkman Healthcare Partners first reported a position in LUNG in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.12M in Q1 2025. 113 funds tracked by Wall St. Rank hold LUNG as of Q1 2026.

Parkman Healthcare Partners held 755,636 shares of Pulmonx worth $975K as of Q1 2026.
Parkman Healthcare Partners bought 27,855 Pulmonx shares in Q1 2026, an estimated $46K.
Pulmonx made up 0.1% of Parkman Healthcare Partners's portfolio in Q1 2026, its #84 holding.
Parkman Healthcare Partners first reported a position in Pulmonx in Q3 2024 and has held it in 7 quarters since.
Parkman Healthcare Partners's Pulmonx position peaked at $4.12M in Q1 2025.
113 funds tracked by Wall St. Rank held Pulmonx as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.